Riccardi, Giovanna <br/><br/>
Tuberculosis Drug Discovery and Development 2019 

 - Basel, Switzerland  MDPI - Multidisciplinary Digital Publishing Institute  2020 
 - 1 electronic resource (296 p.) 
<br/><br/> Open Access 
<br/><br/> Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis and still represents one of the global health threats to mankind. The World Health Organization estimated more than 10 million new cases and reported more than 1.5 million deaths in 2019, thus ranking TB among the main causes of death due to a single pathogen. Standard anti-TB therapy includes four first-line antibiotics that should be administered for at least six months. However, in the case of multi- and extensively drug-resistant TB, second-line medications must be used and these frequently cause severe side effects resulting in poor compliance. Developing new anti-TB drug candidates is therefore of outmost importance. In this Special Issue dedicated to Tuberculosis Drug Discovery and Development, we present the main and latest achievements in the fields of drug and target discovery, host-directed therapy, anti-virulence drugs, and describe the development of two advanced compounds: macozinone and delpazolid. In addition, this Special Issue provides an historical perspective focused on Carlo Forlanini, the inventor of pneumothorax for TB treatment, and includes an overview of the state-of-the-art technologies which are being exploited nowadays in TB drug development. Finally, a summary of TB vaccines that are either approved or undergoing clinical trials concludes the Special Issue. 
<br/><br/><br/>Creative Commons 
<br/><br/><br/>English 
<br/><br/><label>ISBN: </label>books978-3-03943-237-0 9783039432363 9783039432370 
<br/><br/><label>Standard No.: </label>10.3390/books978-3-03943-237-0  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Research & information: general<br/>Biology, life sciences
<br/><br/><label>Subjects--Index Terms: </label>mycobacteria tuberculosis multi-drug resistance drug discovery promiscuous targets Mycobacterium tuberculosis rifampin isoniazid mechanisms of resistance mutations granulomas caseum cell envelope dormancy delpazolid macozinone DprE1 inhibitor clinical studies discovery mode of action drug resistance toxicity target energy metabolism electron transport chain oxidative phosphorylation bedaquiline Q203 MID3 pharmacokinetics pharmacodynamics drug-drug interactions in vitro in vivo drug development tuberculosis treatment biomarkers drug combination clinical trial BCG tuberculosis vaccines TBVI EDCTP IAVI CTVD host-directed therapy anti-virulence compounds TB post-treatment sequelae surgery pulmonary rehabilitation Carlo Forlanini artificial pneumothorax n/a structure-based drug design target-based drug design PknB PknG DNA gyrase antibiotic mycobacterium genomics transcriptomics proteomics metabolomics lipidomics target identification mechanism of action antimicrobial drug resistance (AMR) target-based screening phenotypic screening antituberculosis agents antimycobacterial anti-TB drug pipeline privileged targets lead generation